Biotech bonanza 🥳🪅🎉

FDA approvals and positive results have these stocks firing                                                                                                                                                                                                                                                                                                                                                                                                                 *together with (NYSE: TPET)   Good morning, 360! Just a note Jeff Williams is openlng up Market Navigator NOW (9-11am EST) for all to join his SPY trade of the day → [JOIN NOW](. And here are our top investing ideas toda, be the best prepared trader on the Street! TOVX - Up over 50% in pre-market after receiving FDA orphan drug designation for pancreatic cancer treatment CGTX - Over 15% higher in pre-market after reporting positive Phase 2 results for Alzheimer’s treatment OPK - Up over 28% after FDA approves company’s Pfizer partnered human growth hormone for pediatric patients *A Message on Behalf of Trio Petroleum Corp 🔥 Hot Stock of the Day 🔥 Trio Petroleum Corp (NYSE: TPET) When we’re thinking about the oil sector, our minds typically go straight to the giants —Exxon-Mobil, Shell, and so on… But this little $1 stock, coming fresh off their April IPO, is set to make massive waves in the energy market, with: 👉 High working interest in some of the nation’s richest and most lucrative oil fields 👉 Leadership from one of the world’s largest oil companies 👉 A fantastic market position, as the company pulls up a fresh supply of oil to fill the gap as Saudi Arabia [announces]( another 1 million BPD supply decrease. And this tiny stock is already on the move – up 20% in just the last few days alone. Check out the [company’s website]( and put TPET on top of your trading radar right now! *Sponsored by IA Media LLC, please see disclosures below TOVX - Up over 50% in pre-market after receiving FDA orphan drug designation for pancreatic cancer treatment Theriva Biologics (TOVX), a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. After-market hours yesterday, [the company announced]( it had received orphan drug designation granted by the U.S FDA for VCN-01 for the treatment of Pancreatic Cancer. “The FDA’s decision to grant orphan drug designation to VCN-01 highlights the urgent need for new treatment options for patients with PDAC, which has one of the lowest survival rates among all cancers,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. The FDA’s Office of Orphan Products Development grants orphan status to drugs being developed to treat, diagnose, or prevent a rare disease or condition affecting fewer than 200,000 people in the United States. Orphan Drug Designation is designed to provide drug developers with various benefits to support the development of novel drugs, including the potential for market exclusivity for seven years upon FDA approval, eligibility for tax credits for qualified clinical trials, waiver of application fees, reduced annual product fees, clinical protocol assistance and potential qualification for expedited development programs. TOVX is up over 50% in pre-market on the news. $1.30 has acted as support in the pre-market and will be an important area to watch. Above it, targets to the upside are $1.42, $1.48-$1.50 and then the pre-market high of $1.60. Beyond that, targets are $1.80, $1.90, $2 and then a gap to fill at $2.38. Below $1.30, there is potential support at $1.20, $1, $0.88 and $0.8276. CGTX - Over 15% higher in pre-market after reporting positive Phase 2 results for Alzheimer’s treatment Cognition Therapeutics (CGTX) is a clinical-stage biopharmaceutical company that engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. This morning[the company announced]( positive topline results for its CT1812 Phase 2 SEQUAL study for the treatment of Alzheimer’s disease. The study, which was conducted in the Netherlands, met its primary endpoints for safety and tolerability and showed positive effects for CT1812-treated participants as measured via quantitative electroencephalogram (qEEG). [According to Everard (Jort) Vijverberg](, M.D., Ph.D., principal investigator in SEQUEL, “My colleagues and I are excited to see this favorable result, which suggests that treatment with CT1812 may be directly impacting overall brain health, as illustrated in a change in relative theta power globally and across brain regions.” The stock traded over 15% higher in the pre-market on the news. $2.70 was a support level in the pre-market and will be an important area to watch. Above it, targets to the upside are $2.90, $3 and then the pre-market highs of $3.33. Beyond that, $3.50, $4 and $4.50 come into play. Blow $2.70, there is potential support at $2.60 and then a gap to fill at $2.50. OPK - Up over 28% after FDA approves company’s Pfizer partnered human growth hormone for pediatric patients OPKO Health (OPK) is a healthcare company, engaging in the diagnostics and pharmaceuticals businesses in the United States, and internationally. This morning the company [announced that the FDA had approved]( its Pfizer-OPKE Health partnered NGENLA drug, a once-weekly human growth hormone analog for pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone. The stock traded up over 28% on the news in pre-market. The $1.90 level has acted as support in the pre-market and will be an important area to watch. Above it, targets to the upside are $2 and then the pre-market high at $2.20. Beyond that, $2.25, $2.50, $2.60, $2.80 and then $3 come into play. Below $1.90, there is potential support at $1.80, $1.70 and then a gap to fill at $1.66. [Economic Calendar]( To Your Success! *please see disclosures below Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions *PAID ADVERTISEMENT. RagingBull has been paid fifteen thousand dollars by ach bank transfer by IA Media LLC for advertising Trio Petroleum Corp from a period beginning on June 28, 2023 through June 29, 2023 of the same year. As a result of this advertisement and other marketing efforts, RagingBull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull do not hold a position in Trio Petroleum Corp. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Trio Petroleum Corp, increased trading volume, and possibly an increased share price of the Trio Petroleum Corp securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. In cases where a third party is involved, please note we have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www. sec. gov/edgar/ searchedgar/companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. [Ragingbull.com](, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](